Seattle-based Talus Bioscience has raised $11.2M in an early fundraising round, money that will go toward advancing the biotech’s portfolio of preclinical cancer programs and help build out the biotech’s drug discovery platform. Talus Bio is targeting a challenging transcription factor linked to prostate cancer, plus brachyury-driven cancers.
Talus Bio is targeting a challenging transcription factor linked to prostate cancer, plus brachyury-driven cancers. Brachyury is a transcription factor that regulates tumor development in chordoma—a rare bone tumor that forms in the spine or base of the skull.
Transcription factors are genome-regulating proteins that can direct which genes are turned on or off. However, when the process goes awry, the proteins can drive certain disease processes, such as cancer, diabetes, inflammatory diseases, fibrosis and neurological conditions.